Imricor Medical Systems Submits 3D Mapping System for CE Mark Approval in Europe; Shares Up 7%

MT Newswires Live09:24

Imricor Medical Systems (ASX:IMR) submitted the NorthStar 3D mapping system for CE Mark approval in Europe, marking the final stage before commercial rollout across Europe and the Middle East, according to a Monday filing with the Australian bourse.

The company anticipates US Food and Drug Administration approval for its consumable ablation tools in the second half of 2025 with NorthStar's expedited approval processes in Europe and the US, the filing said.

Meanwhile, the first-in-human ventricular tachycardia ablation guided by real-time magnetic resonance imaging will take place next year, according to the filing.

Shares rose nearly 7% in morning trade Monday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2493274715?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-23 09:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2493274715","market":"sg","top_or_hot":-1,"title":"Imricor Medical Systems Submits 3D Mapping System for CE Mark Approval in Europe; Shares Up 7%","media":"MT Newswires Live","content":"<html><body><p> Imricor Medical Systems (ASX:IMR) submitted the NorthStar 3D mapping system for CE Mark approval in Europe, marking the final stage before commercial rollout across Europe and the Middle East, according to a Monday filing with the Australian bourse.</p><p>The company anticipates US Food and Drug Administration approval for its consumable ablation tools in the second half of 2025 with NorthStar's expedited approval processes in Europe and the US, the filing said.</p><p>Meanwhile, the first-in-human ventricular tachycardia ablation guided by real-time magnetic resonance imaging will take place next year, according to the filing.</p><p>Shares rose nearly 7% in morning trade Monday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Imricor Medical Systems Submits 3D Mapping System for CE Mark Approval in Europe; Shares Up 7%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImricor Medical Systems Submits 3D Mapping System for CE Mark Approval in Europe; Shares Up 7%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-23 09:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Imricor Medical Systems (ASX:IMR) submitted the NorthStar 3D mapping system for CE Mark approval in Europe, marking the final stage before commercial rollout across Europe and the Middle East, ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2493274715","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2493274715","pubTimestamp":1734917060,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Imricor Medical Systems  submitted the NorthStar 3D mapping system for CE Mark approval in Europe, marking the final stage before commercial rollout across Europe and the Middle East, according to a Monday filing with the Australian bourse.The company anticipates US Food and Drug Administration approval for its consumable ablation tools in the second half of 2025 with NorthStar's expedited approval processes in Europe and the US, the filing said.Meanwhile, the first-in-human ventricular tachycardia ablation guided by real-time magnetic resonance imaging will take place next year, according to the filing.Shares rose nearly 7% in morning trade Monday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","CE":"塞拉尼斯","IMR.AU":"IMRICOR MEDICAL SYSTEMS-CDI","BK7503":"科技股","BK4109":"特种化学制品","BK7508":"医药生物股","BK7007":"医疗保健设备","BK4585":"ETF&股票定投概念"},"translate_title":"Imricor Medical Systems提交3D测绘系统在欧洲获得CE标志批准；股价上涨7%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CE":1,"IMR.AU":0.9},"content_text":"Imricor Medical Systems (ASX:IMR) submitted the NorthStar 3D mapping system for CE Mark approval in Europe, marking the final stage before commercial rollout across Europe and the Middle East, according to a Monday filing with the Australian bourse.The company anticipates US Food and Drug Administration approval for its consumable ablation tools in the second half of 2025 with NorthStar's expedited approval processes in Europe and the US, the filing said.Meanwhile, the first-in-human ventricular tachycardia ablation guided by real-time magnetic resonance imaging will take place next year, according to the filing.Shares rose nearly 7% in morning trade Monday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2493274715"}